利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.022 秒)

    SOLUBLE PROTEINS FOR USE AS THERAPEUTICS
    1.
    发明申请
    SOLUBLE PROTEINS FOR USE AS THERAPEUTICS 审中-公开
    可溶性蛋白用作治疗药物

    公开(公告)号：US20140193408A1

    公开(公告)日：2014-07-10

    申请号：US14126223

    申请日：2012-06-15

    申请人： Thomas Huber ,  Frank Kolbinger ,  Karl Welzenbach

    发明人： Thomas Huber ,  Frank Kolbinger ,  Karl Welzenbach

    IPC分类号： C07K16/28 ,  C07K14/705

    CPC分类号： C07K16/2896 ,  C07K14/70596 ,  C07K16/241 ,  C07K16/2803 ,  C07K16/44 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/92 ,  C07K2319/32

    摘要： The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having VH, CH1, CH2, and CH3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the VH region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a VL and CL region; and (d) a monovalent region of a mammalian binding molecule fused to the VL region; characterised in that each pair of VH and VL CDR sequences has specificity for an antigen, such that the total valency of said soluble protein is six. The invention further relates to soluble SIRPa-binding antibody-like proteins as shown in FIG. 1.

    摘要翻译： 本发明涉及改进的结合蛋白，用作药物，特别是用于预防或治疗自身免疫性和炎症性疾病，例如过敏性哮喘和炎症性肠病。 本发明更具体地涉及包含两个异二聚体复合物的可溶性蛋白质，其中每个异二聚体基本上由以下组成：（i）第一单链多肽，其包含：（a）具有VH，CH1，CH2和 CH3区; 和（b）与VH区融合的哺乳动物结合分子的单价区域; 和（ii）第二单链多肽，其包含：（c）具有VL和CL区的抗体轻链序列; 和（d）与VL区融合的哺乳动物结合分子的单价区域; 其特征在于每对VH和VL CDR序列对抗原具有特异性，使得所述可溶性蛋白的总价为6。 本发明还涉及如图1所示的可溶性SIRPA结合抗体样蛋白质。 1。

    SOLUBLE PROTEINS FOR USE AS THERAPEUTICS
    2.
    发明申请
    SOLUBLE PROTEINS FOR USE AS THERAPEUTICS 审中-公开
    可溶性蛋白用作治疗药物

    公开(公告)号：US20130011401A1

    公开(公告)日：2013-01-10

    申请号：US13517989

    申请日：2010-12-21

    申请人： Thomas Huber ,  Frank Kolbinger ,  Marie Sarfati ,  Karl Welzenbach

    发明人： Thomas Huber ,  Frank Kolbinger ,  Marie Sarfati ,  Karl Welzenbach

    IPC分类号： A61K39/395 ,  C12N15/62 ,  C12N15/63 ,  C12N5/10 ,  G01N33/53 ,  A61P29/00 ,  A61P11/06 ,  A61P37/08 ,  A61P1/00 ,  A61P19/02 ,  C07K16/46 ,  C12P21/02

    CPC分类号： C07K14/70503 ,  A61K38/00 ,  C07K14/70596 ,  C07K2319/30

    摘要： The present invention relates to soluble SIRPα binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRPα binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRPα binding domain fused at the N-terminal part of a heavy chain constant region of an antibody; and, (ii) a second monovalent single chain polypeptide comprising a second SIR % binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRP-binding antibody-like protein as shown in FIG. 1.

    摘要翻译： 本发明涉及用作药物的可溶性SIRPα结合蛋白，特别是用于预防或治疗自身免疫性和炎症性疾病，例如过敏性哮喘和炎症性肠病。 本发明更具体地涉及包含两个异二聚体复合物的可溶性SIRPα结合蛋白，其中每个异二聚体基本上由以下组成：（i）第一单价单链多肽，其包含在沉重的N末端部分融合的第一个SIRPα结合结构域 抗体的链恒定区; 和（ii）第二单价单链多肽，其包含在抗体的CL轻链恒定区的N末端部分融合的第二SIR％结合结构域。 本发明还涉及如图1所示的可溶性SIRP结合抗体样蛋白。 1。

    Therapeutic binding molecules
    3.
    发明申请
    Therapeutic binding molecules 失效
    治疗结合分子

    公开(公告)号：US20060088525A1

    公开(公告)日：2006-04-27

    申请号：US11297317

    申请日：2005-12-08

    申请人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

    发明人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

    IPC分类号： A61K39/395 ,  C07K16/44

    CPC分类号： C07K16/289 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

    摘要： A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

    摘要翻译： 包含至少一个抗原结合位点的分子，其包含高变区CDR1，CDR2和CDR3，所述CDR1具有氨基酸序列Asn-Tyr-Ile-Ile-His（NYIIH），所述CDR2具有氨基酸序列Tyr -Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly（YFNPYNHGTKYNEKFKG）和具有氨基酸序列Ser-Gly-Pro-Tyr -Ala-Trp-Phe-Asp-Thr（SGPYAWFDT）; 例如 进一步包含具有氨基酸序列Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln（RASQNIGTSIQ）的高变区CDR1'，CDR2'和CDR3'，CDR1'，CDR2' 具有氨基酸序列Ser-Ser-Ser-Glu-Ser-Ile-Ser（SSSESIS）和具有氨基酸序列Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr（QQSNTWPFT）的CDR3' 例如 可用作药物的嵌合或人源化抗体。

    Therapeutic binding molecules
    7.
    发明申请
    Therapeutic binding molecules 审中-公开
    治疗结合分子

    公开(公告)号：US20050069538A1

    公开(公告)日：2005-03-31

    申请号：US10666332

    申请日：2003-09-18

    申请人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

    发明人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

    IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/44

    CPC分类号： C07K16/289 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

    摘要： A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

    摘要翻译： 包含至少一个抗原结合位点的分子，其包含高变区CDR1，CDR2和CDR3，所述CDR1具有氨基酸序列Asn-Tyr-Ile-Ile-His（NYIIH），所述CDR2具有氨基酸序列Tyr -Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly（YFNPYNHGTKYNEKFKG）和具有氨基酸序列Ser-Gly-Pro-Tyr -Ala-Trp-Phe-Asp-Thr（SGPYAWFDT）; 例如 进一步包含具有氨基酸序列Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin（RASQNIGTSIQ）的高变区CDR1'，CDR2'和CDR3'，CDR1'，CDR2' 具有氨基酸序列Ser-Ser-Ser-Glu-Ser-Ile-Ser（SSSESIS）和具有氨基酸序列Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr（QQSNTWPFT）的CDR3' 例如 可用作药物的嵌合或人源化抗体。

    Therapeutic binding molecules
    9.
    发明授权
    Therapeutic binding molecules 失效
    治疗结合分子

    公开(公告)号：US07825222B2

    公开(公告)日：2010-11-02

    申请号：US11297317

    申请日：2005-12-08

    申请人： Gregorio Aversa ,  Frank Kolbinger ,  Josè M Carballido Herrera ,  András Aszódi ,  José W Saldanha ,  Bruce M Hall

    发明人： Gregorio Aversa ,  Frank Kolbinger ,  Josè M Carballido Herrera ,  András Aszódi ,  José W Saldanha ,  Bruce M Hall

    IPC分类号： C07K16/00 ,  C07K16/46

    CPC分类号： C07K16/289 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

    摘要： A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

    摘要翻译： 包含至少一个抗原结合位点的分子，其包含高变区CDR1，CDR2和CDR3，所述CDR1具有氨基酸序列Asn-Tyr-Ile-Ile-His（NYIIH），所述CDR2具有氨基酸序列Tyr -Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly（YFNPYNHGTKYNEKFKG）和具有氨基酸序列Ser-Gly-Pro-Tyr -Ala-Trp-Phe-Asp-Thr（SGPYAWFDT）; 例如 进一步包含具有氨基酸序列Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln（RASQNIGTSIQ）的高变区CDR1'，CDR2'和CDR3'，CDR1'，CDR2' 具有氨基酸序列Ser-Ser-Ser-Glu-Ser-Ile-Ser（SSSESIS）和具有氨基酸序列Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr（QQSNTWPFT）的CDR3' 例如 可用作药物的嵌合或人源化抗体。